Dow, S&P 500, Nasdaq futures slide after Trump orders Hormuz blockade against Iran

April 13, 2026

Dow, S&P 500, Nasdaq futures slide after Trump orders Hormuz blockade against Iran

Breaking News

Image source: Adobe Stock



US stock futures traded lower on Monday, but recouped some of the losses that came after President Trump ordered a US blockade of the Strait of Hormuz following the collapse of US-Iran negotiations.

Dow Jones Industrial Average futures were down roughly 0.5%, or around 200 points, after sinking as much as 580 points.

Contracts on the S&P 500 and Nasdaq 100 dropped roughly 0.5% as a surge in oil prices revived concerns about inflationary pressure and potential drag on global growth.

Trump's move to block all maritime traffic through the Strait of Hormuz looks set to escalate already high-running Middle East tensions.

That has piled on even more risk for markets whose hopes for a cessation in hostilities were dented by the breakdown in negotiations in Islamabad.

"Effective immediately, the United States Navy, the Finest in the World, will begin the process of BLOCKADING any and all Ships trying to enter, or leave, the Strait of Hormuz," Trump wrote on Truth Social.

The halt is scheduled to start at 10 a.m. ET on Monday. Yahoo Finance reports.

EdgeUp

🛢️ BP strengthens exploration pipeline with Namibia offshore play

BP p.l.c. shares traded higher in Monday's premarket session, even as broader indices pointed lower, supported by a risk-on tone across the energy sector.

The company said Monday it has agreed to acquire a 60% stake in three offshore exploration blocks, PEL 97, PEL 99, and PEL 100, in Namibia's Walvis Basin from Eco Atlantic Oil & Gas, subject to regulatory approvals.

BP will operate the assets, while Eco Atlantic and NAMCOR will retain minority stakes.

"Namibia is a region attracting growing industry interest…," said Gordon Birrell, BP's executive vice president of production & operations, highlighting long-term growth potential.

The deal builds on BP's recent exploration momentum, including multiple discoveries through Azule Energy, its joint venture with ENI S.p.A. Benzinga reports.


🥤 McDonald's to add energy drinks, crafted sodas to US menus, WSJ reports

McDonald's is preparing to introduce a Red Bull Dragonberry Energizer as part of a broader revamp of its cold drink menu at its U.S. restaurants later this year, the Wall Street Journal reported on Sunday, citing company documents.

The new beverages, slated to roll out next month, include a Dirty Dr Pepper and a Mango Pineapple Refresher, the report said. Reuters reports. MarketWatch reports.


🧬 IDEAYA eye cancer drug combo meets main goal of mid-to-late-stage trial

IDEAYA Biosciences said on Monday its drug for a type of eye cancer met the main goal of a mid-to-late-stage trial, after showing improvement in patients' survival without progression of the disease, sending its shares 39.2% higher in premarket trade.

The drug, darovasertib, in combination with Pfizer's Xalkori, improved survival by a median of 6.9 months versus 3.1 months for other therapies chosen by the trial's investigator.

There were five complete responses, or disappearance of all detectable signs of cancer, observed in the darovasertib combination arm. Yahoo Finance reports.


🧠 Keep calm and carry on buying the dip, says JPMorgan

Any investor who has a time horizon of at least three months should use any weakness in stocks to buy, says a new research note from JPMorgan strategists.

Mislav Matejka leads the JPMorgan team and in an equity strategy note published Monday he warns investors against “succumbing to bearish views” because he believes the various political, economic and military constraints against that geopolitical escalation are largely intact.

Even three weeks into the conflict, Matejka and team were advising clients that oversold signals had begun to appear and their conviction in that view appears to be solidifying. MarketWatch reports.


⚠️ ‘Big Short’ Michael Burry sends signal on Nvidia stock

Short-seller Michael Burry just made his view on Nvidia stock a lot harder to ignore.

In a new Substack post, the popular investor disclosed that he added to his bearish Nvidia position, loading up more on long-dated puts, with the stock still at the heart of the AI rally.

At the same time, he scooped up shares in the biggest Chinese tech companies, such as Alibaba and JD.com. Yahoo Finance reports.

Top 5 Movers in Early Pre-Market

(All pricing and percent gains are based on Early Pre-Market from 4:00 AM to 7:00 AM Eastern Time)
Stock Analysis reports.


1) JDZG: JIADE Limited

Total gain: +43.09%

2) SKYQ: Sky Quarry Inc.
Total gain: +35.74%

3) BATL: Battalion Oil Corporation
Total gain: +28.13%

4) IMA: ImageneBio, Inc.
Total gain: +23.63%

5) ALMU: Aeluma, Inc.
Total gain: +22.77%

Yesterday’s Biggest Movers

The closing price of the top three market percent gainers trading near or above $3 on April 10.
Stock Analysis reports.

*All pricing and percent gains are based on regular market trading hours from 9:30am to 4:00pm Eastern Time

1) AKAN: Akanda Corp.
Total gain: +324.89%
The company announced that it expects to implement a 1-for-4.5 reverse stock split of the Company's common shares effective April 13, 2026. The reverse stock split was previously approved by the Company's shareholders on November 28, 2025 and Board of Directors on March 23, 2026 and will begin trading on an adjusted basis giving effect to the reverse stock split at the opening of market on April 13, 2026 under the existing ticker symbol "AKAN". The new CUSIP number of the Company's common shares will be 00971M700 and the new ISIN code will be CA00971M7008. Newsfile Corp reports.

2) SKYQ: Sky Quarry Inc.
Total gain: +72.70%
The stock appeared to be moving on no notable news.

3) ZNTL: Zentalis Pharmaceuticals, Inc.
Total gain: +49.55%
The company announced the selection of 400mg once daily on a 5-days-on, 2-days-off schedule (400mg QD 5:2) as the optimal monotherapy dose of azenosertib in patients with Cyclin E1-positive platinum-resistant ovarian cancer (PROC) based on the prespecified interim data analysis from DENALI Part 2a. This dose will be carried forward in the ongoing potentially pivotal DENALI Phase 2 clinical trial as well as the confirmatory ASPENOVA Phase 3 clinical trial. Globe Newswire reports.

Today’s Economic Dates

Time (ET)/ Report/ Period

10:00 AM - Existing home sales - March
6:20 PM - Fed governor Stephen Miran speaks - N/A

Today’s Notable Earnings

*Estimate and Actual numbers represent Earnings Per Share in US Dollars


GS: Goldman Sachs Gr
Q1 2026
Before Market Open
Estimate: 16.370
Actual: N/A

FAST: Fastenal
Q1 2026
Before Market Open
Estimate: 0.300
Actual: N/A

FBK: FB Financial
Q1 2026
After Market Close
Estimate: 1.120
Actual: N/A

Parting Thoughts

“If you can’t take a small loss, sooner or later you will take the mother of all losses.”

– Ed Seykota

Sourced in: Trading interviews — GoodReads.

Disclaimer

TradeZero America, Inc., a United States broker dealer, registered with the Securities and Exchange Commission (SEC) and member of the Financial Industry Regulatory Authority (FINRA) and the Securities Investor Protection Corporation (SIPC); TradeZero, Inc., a Bahamian broker dealer, registered with the Securities Commission of the Bahamas ; TradeZero Canada Securities ULC, a Canadian broker dealer, member firm of Canadian Investment Regulatory Organization (CIRO) and member of the Canadian Investor Protection Fund (CIPF); and TradeZero Europe B.V., a Dutch broker dealer, authorized and regulated by the Dutch Authority for the Financial Markets (AFM) (collectively, the “TradeZero Broker Dealers”).

TradeZero Broker Dealers offer self-directed electronic securities trading to their customers. TradeZero Broker Dealers do not provide financial or trading advice and do not make investment recommendations to their customers. This communication does not constitute an offer to sell or a solicitation to buy any security or instrument which it may reference. There is a risk of loss in online trading of securities including equities and options. Trading on margin is for experienced investors whereby the loss can be greater than your initial investment. Likewise, short selling as a securities trading strategy is extremely risky and can lead to potentially unlimited losses. Options trading is not suitable for all investors as it can involve risk that may expose investors to significant losses. Please read the Characteristics and Risks of Standardized Options, also known as the Options Disclosure Document (ODD) at OCC.

If you have any specific questions about TradeZero's brokerage services, please reach out to the TradeZero Broker Dealer servicing your jurisdiction.